분자 및 혈액 기반 바이오마커, 치료 및 결과를 위한 두경부암종 임상 연구 플랫폼 (HEAT)
분자 및 혈액 기반의 두경부암 임상 연구 플랫폼
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The advent of checkpoint inhibitors has changed the treatment landscape in SCCHN and new treatment sequences have entered clinical practice.
More in-depth knowledge of tumor biomarkers are important measures for optimization of treatment strategies in SCCHN. In addition to this, investigations may involve other assessments, which will be explored separately, such as molecular testing. These tests are then linked to the core data set and will allow to associate such measures with outcomes. This concept is flexible and allows for rapid integration of contemporary research questions in a timely manner.
Furthermore, insights into the treatment reality for recurrent/metastatic salivary gland carcinoma and other rare tumor entities (SNUC, etc.) are urgently needed, as there is currently no established standard of care.
The monoclonal antibody cetuximab in combination with platinum and fluorouracil (EXTREME) has been the standard of care for recurrent or metastatic (r/m) SCCHN for over a decade.1 Recently, the immune checkpoint inhibitors (CPIs) nivolumab and pembrolizumab have changed the therapeutic landscape of patients with r/m SCCHN. Nivolumab is considered as therapeutic standard after failure of platinum-based therapy based on the results of the phase III Checkmate-141 trial.2 In addition, pembrolizumab has become the new standard in the first-line setting in combination with platinum/fluorouracil chemotherapy or as monotherapy for patients with programmed cell death ligand 1 (PD-L1) positive tumors based on the data from the phase III Keynote-048 trial.3 Moreover, cetuximab in combination with platinum and docetaxel (TPEx) has emerged as a less toxic alternative to the EXTREME regimen.4 Due to the shifting first-line treatment landscape, data to guide contemporary 2nd line therapy are scarce and the optimal treatment sequence remains vague.2,5,6 The implementation of biomarkers and selection of patients in a real-world setting are areas of academic interest. In addition, the assessment of treatment outcomes in rare entities are underrepresented in pivotal trials, and as a matter of fact, may be completely excluded. However, broad labels permit the use of novel agents, but a larger body of evidence is needed to substantiate such treatment choices. HEAT seeks to address these questions by inclusion of a real-world patient population and continuous assessment of oncological outcomes by means of a core clinical data set implemented into HEAT.
Overall, HEAT is a study platform, which continuously assesses clinical outcomes and modularly integrates additional measures to enable rapid answers to research questions.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Project Manager
- 전화번호: +49 (0)30 814534431
- 이메일: kht-register@aio-studien-ggmbh.de
연구 장소
-
-
-
Essen, 독일, 45147
- 아직 모집하지 않음
- Universitätsklinikum Essen
-
연락하다:
- Michael Pogorzelski, Dr. med.
- 전화번호: +49 (0) 157 38 79 55 41
- 이메일: Michael.Pogorzelski@uk-essen.de
-
Hanover, 독일, 30161
- 모병
- Onkologie/Studienzentrum am Raschplatz GbR
-
연락하다:
- Eyck von der Heyde, Dr. med.
- 전화번호: +49 (0) 511 86649985
- 이메일: vdheyde@onkologie-am-raschplatz.de
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult patients with histologically or cytologically confirmed malignancy of the head neck area including but not limited to
- squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx
- not amenable for curative treatment who receive palliative systemic treatment or best supportive care.
설명
Inclusion Criteria:
- Age ≥ 18 years
- Able to understand and willing to sign written informed consent
- Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
- Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
- Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Exclusion Criteria: none
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_ONLY
- 시간 관점: PROSPECTIVE
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Sociodemographic factors
기간: 3 years
|
Highest level of education, Employment status, Current professional activity, Professional risk factors, Level of self-sufficiency, Care degree |
3 years
|
|
Treatments
기간: 3 years
|
Types of local therapies (surgery, radiotherapy, radiochemotherapy), systemic therapy and therapeutic sequences |
3 years
|
|
Response rates
기간: 3 years
|
Response rates |
3 years
|
|
Treatment decision
기간: 3 years
|
Physician-reported parameters affecting treatment decision |
3 years
|
|
Progression-free survival
기간: 3 years
|
Progression-free survival |
3 years
|
|
Time-to-treatment-failure
기간: 3 years
|
Time-to-treatment-failure |
3 years
|
|
Overall survival
기간: 3 years
|
Overall survival |
3 years
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 연구 책임자: Victor Grünwald, Prof. Dr., Universitätsklinikum Essen
- 수석 연구원: Michael Pogorzelski, Dr., Universitätsklinikum Essen
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- AIO-KHT-0322/ass
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .